يعرض 1 - 10 نتائج من 16 نتيجة بحث عن '"NASH non-alcoholic steatohepatitis"', وقت الاستعلام: 0.82s تنقيح النتائج
  1. 1

    المصدر: Computational and Structural Biotechnology Journal, Vol 19, Iss, Pp 5920-5930 (2021)
    Computational and Structural Biotechnology Journal

  2. 2

    المساهمون: Francque, Sven M, Marchesini, Giulio, Kautz, Achim, Walmsley, Martine, Dorner, Rebecca, Lazarus, Jeffrey V, Zelber-Sagi, Shira, Hallsworth, Kate, Busetto, Luca, Frühbeck, Gema, Dicker, Dror, Woodward, Euan, Korenjak, Marko, Willemse, José, Koek, Gerardus H, Vinker, Shlomo, Ungan, Mehmet, Mendive, Juan M, Lionis, Christos, Interne Geneeskunde, MUMC+: MA Maag Darm Lever (9), RS: NUTRIM - R2 - Liver and digestive health

    المصدر: JHEP Reports
    JHEP Reports, Vol 3, Iss 5, Pp 100322-(2021)
    JHEP Reports, 3(5):100322. Elsevier BV

    مصطلحات موضوعية: NASH, non-alcoholic steatohepatiti, Y GASTRIC BYPASS, Disease, RC799-869, PLACEBO-CONTROLLED TRIAL, LIFE-STYLE MODIFICATION, cardiovascular disease, LDL, low-density lipoprotein, HEPATOCELLULAR-CARCINOMA, non-invasive test, T2D, GLP-1 RAs, glucagon-like receptor 1 agonists, European Association for the Study of Obesity, HCC, Gastroenterology, NASH, specific, Diseases of the digestive system. Gastroenterology, CAP, controlled attenuation parameter, CT, computed tomography, FXR, ASH, alcoholic steatohepatitis, GP, non-alcoholic steatohepatitis, GLP-1 RAs, glucagon-like receptor 1 agonist, LDL, low-density lipoproteins, medicine.medical_specialty, HDL, achievable, NASH, non-alcoholic steatohepatitis, T2D, type 2 diabetes, high-density lipoprotein, CVD, cardiovascular disease, LDL, Patient Guideline, Quality of life (healthcare), FXR, farnesoid X receptor, NAFLD, low-density lipoproteins, GP, general practitioner, NAFL, non-alcoholic fatty liver, FIB-4, fibrosis-4 index, Intensive care medicine, computed tomography, Guideline, medicine.disease, T1D, type 1 diabete, digestive system diseases, NIT, Human medicine, farnesoid X receptor, type 1 diabetes, BMI, body mass index, EASL, European Association for the Study of the Liver, Placebo-controlled study, Chronic liver disease, GLP-1 RAs, QUALITY-OF-LIFE, alcoholic steatohepatitis, European Association for the Study of Diabetes, EASD, European Association for the Study of Diabetes, Immunology and Allergy, magnetic resonance imaging, NASH Clinical Research Network, ALD, alcohol-related or alcoholic liver disease, Disease management (health), glucagon-like receptor 1 agonists, EASO, European Association for the Study of Obesity, NASH CRN, NASH Clinical Research Network, ASH, alcoholic steatohepatiti, Fatty liver, timely, hepatocellular carcinoma, CVD, magnetic resonance elastography, MRE, NAFL, FIB-4, non-alcoholic fatty liver, type 2 diabetes, T1D, type 1 diabetes, CAP, controlled attenuation parameter, CT, European Association for the Study of the Liver, MRI, fibrosis-4 index, NAFLD, non-alcoholic fatty liver disease, EASD, HDL, high-density lipoprotein, UNITED-STATES, ASH, body mass index, EASL, measurable, BMI, NIT, non-invasive test, Internal Medicine, medicine, NASH CRN, HEPATIC STEATOSIS, HCC, hepatocellular carcinoma, MRE, magnetic resonance elastography, MRI, magnetic resonance imaging, SMART, specific, measurable, achievable, relevant, timely, Disease burden, BARIATRIC SURGERY, Hepatology, SMART, business.industry, SERUM ALANINE AMINOTRANSFERASE, non-alcoholic fatty liver disease, PHYSICAL-ACTIVITY, alcohol-related or alcoholic liver disease, EASD, European Association for the Study of Diabete, EASO, ALD, general practitioner, relevant, T1D, business

    وصف الملف: ELETTRONICO

  3. 3

    المساهمون: LESUR, Hélène, Impact du métabolisme des acides gras des tissus adipeux et du foie sur l'insulinorésistance - - HepAdialogue2017 - ANR-17-CE14-0015 - AAPG2017 - VALID, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Catholique de Louvain = Catholic University of Louvain (UCL), ToxAlim (ToxAlim), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Ecole d'Ingénieurs de Purpan (INPT - EI Purpan), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Toxicologie Intégrative & Métabolisme (ToxAlim-TIM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Toulouse III - Paul Sabatier (UT3), Lucia Parlati and Catherine Postic received funding from the French association for the study of the liver (AFEF). Catherine Postic and Herve Guillou received funding from the Agence Nationale de la Recherche (ANR-17-CE14-0015Hepadialogue)., ANR-17-CE14-0015,HepAdialogue,Impact du métabolisme des acides gras des tissus adipeux et du foie sur l'insulinorésistance(2017), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP)

    المصدر: JHEP Reports
    JHEP Reports Innovation in Hepatology
    JHEP Reports Innovation in Hepatology, 2021, 3 (6), pp.100346. ⟨10.1016/j.jhepr.2021.100346⟩
    JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (6), pp.100346. ⟨10.1016/j.jhepr.2021.100346⟩

    مصطلحات موضوعية: HFD, high-fat diet, SREBP-1c, [SDV]Life Sciences [q-bio], Disease, Review, ACC, acetyl-CoA carboxylase, ASK1, apoptosis signal-regulating kinase 1, Chronic liver disease, Bioinformatics, ChREBP, carbohydrate responsive element–binding protein, PPARα, NEFA, TNF-α, tumour necrosis factor-α, 0302 clinical medicine, Fibrosis, Immunology and Allergy, Medicine, IL-, interleukin, VLDL, very low-density lipoprotein, 0303 health sciences, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, NEFA, non-esterified fatty acid, Fatty liver, Gastroenterology, NASH, lipotoxicity, FAS, fatty acid synthase, animal models, 3. Good health, [SDV] Life Sciences [q-bio], PY, persons/years, Lipotoxicity, FXR, Saturated fatty acid, JNK, c-Jun N-terminal kinase, 030211 gastroenterology & hepatology, LXR, CAP, controlled attenuation parameter, HSL, hormone-sensitive lipase, HSC, hepatic stellate cells, GGT, gamma glutamyltransferase, NAFLD, non-alcoholic fatty liver disease, ChREBP, NASH, non-alcoholic steatohepatitis, SFA, saturated fatty acid, TCA, tricarboxylic acid, Phf2, histone demethylase plant homeodomain finger 2, digestive system, 03 medical and health sciences, glucotoxicity, FXR, farnesoid X receptor, NAFLD, FFA, free fatty acid, Internal Medicine, RCT, randomised controlled trial, Liver X receptor, PPARa, 030304 developmental biology, FGF21, fibroblast growth factor-21, MCD, methionine- and choline-deficient, HVPG, hepatic venous pressure gradient, Hepatology, business.industry, PUFAs, polyunsaturated fatty acids, nutritional and metabolic diseases, TLR4, Toll-like receptor 4, SCD1, stearoyl-CoA desaturase-1, medicine.disease, digestive system diseases, PPARα, peroxisome proliferator-activated receptor-α, SREBP-1c, sterol regulatory element–binding protein-1c, Steatosis, LXR, liver X receptor, business, HCC, hepatocellular carcinoma, MUFA, monounsaturated fatty acids, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology

    وصف الملف: application/pdf

  4. 4
  5. 5

    المصدر: Erhardtsen, E, Rasmussen, D G K, Frederiksen, P, Leeming, D J, Shevell, D, Gluud, L L, Karsdal, M A, Aithal, G P & Schattenberg, J M 2021, ' Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis ', JHEP Reports, vol. 3, no. 4, 100317 . https://doi.org/10.1016/j.jhepr.2021.100317Test
    JHEP Reports, Vol 3, Iss 4, Pp 100317-(2021)
    JHEP Reports

    وصف الملف: application/pdf

  6. 6
  7. 7
  8. 8

    المصدر: JHEP Reports, Vol 2, Iss 5, Pp 100142-(2020)
    JHEP Reports

  9. 9

    المصدر: Burra, Patrizia; Becchetti, Chiara; Germani, Giacomo (2020). NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP reports, 2(6), p. 100192. Elsevier 10.1016/j.jhepr.2020.100192 <http://dx.doi.org/10.1016/j.jhepr.2020.100192Test>
    JHEP Reports

    وصف الملف: application/pdf

  10. 10

    المساهمون: Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)

    المصدر: JHEP Reports Innovation in Hepatology
    JHEP Reports Innovation in Hepatology, Elsevier, 2021, 3 (2), pp.100219. ⟨10.1016/j.jhepr.2020.100219⟩
    JHEP Reports